AMGN


Company Update (NASDAQ:AMGN): Amgen, Inc. Highlights Key Clinical Data To Be Presented At European Cancer Congress 2015

Amgen, Inc. (NASDAQ:AMGN) announced it will present data from its oncology portfolio and pipeline at the European Cancer Congress 2015 (ECC 2015), Sept.

Stock Update (NASDAQ:AMGN): Amgen, Inc. Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha

Amgen, Inc. (NASDAQ:AMGN) announced the submission of an application to the U.

Tuesday’s Top Upgrades: Bank of America Corp (BAC), Amgen, Inc. (AMGN), Regeneron Pharmaceuticals Inc (REGN), Achillion Pharmaceuticals, Inc. (ACHN)

A number of Wall Street analysts weighed in on their favorite stocks this morning before market open. Below are the most notable analyst …

Amgen Inc (AMGN) Receives Drug Approval, Analysts Have Mixed Reviews

Amgen, Inc.’s (NASDAQ:AMGN) cholesterol-reducing drug, Repatha, was approved by the FDA last week, nearly a month after it was already approved by European …

Stock Update (NASDAQ:AMGN): Amgen, Inc. Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide To The European Medicines Agency

Amgen, Inc. (NASDAQ:AMGN) announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for etelcalcetide …

Company Update (NASDAQ:AMGN): Amgen, Inc. Enters Into Neuroscience Collaboration With Novartis For Alzheimer’s Disease And Migraine Programs

Amgen, Inc. (NASDAQ:AMGN) announced a neuroscience collaboration with Novartis in the areas of Alzheimer’s disease and migraine.

Stock Update (NASDAQ:AMGN): Amgen, Inc. And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide

Amgen, Inc. (NASDAQ:AMGN) and UCB announced top-line results from the STRUCTURE trial (STudy evaluating effect of RomosozUmab Compared with Teriparatide in postmenopaUsal women with …

Piper Jaffray Weighs In on Amgen, Inc. (AMGNׁ) Following Repatha FDA Approval

Piper Jaffray’s healthcare analyst Joshua Schimmer weighed in with his views on Amgen, Inc. (NASDAQ:AMGN), following the news that the company received FDA approval for its PCSK9 inhibitor …

Stock Update (NASDAQ:AMGN): FDA Approves Amgen, Inc.’s New Cholesterol-Lowering Medication Repatha

Amgen, Inc. (NASDAQ:AMGN) announced that the U.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts